Kamada LtdNASDAQ:KMDA
- LAST PRICE5.2700
- TODAY'S CHANGE (%)0.0500 (0.9579%)
- Bid / Lots5.2300/ 12
- Ask / Lots6.0500/ 1
- Open / Previous Close5.2200 / 5.2200
- Day Range
- 52 Week Range
- Volume5,686
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KMDA |
|---|---|---|
| 09:32 ET | 1031 | 5.22 |
| 09:57 ET | 100 | 5.17 |
| 10:19 ET | 882 | 5.2 |
| 11:04 ET | 456 | 5.18 |
| 11:08 ET | 912 | 5.16 |
| 11:11 ET | 340 | 5.16 |
| 02:13 ET | 100 | 5.2 |
| 03:12 ET | 565 | 5.2 |
| 03:56 ET | 100 | 5.27 |
May 9, 2024
DJ Kamada Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 7:44AM ET on Thursday May 09, 2024 by Dow Jones
7:44AM ET on Thursday May 09, 2024 by Dow Jones
May 8, 2024
Press Release: Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance, from 7:00AM ET on Wednesday May 08, 2024 by Dow Jones
7:00AM ET on Wednesday May 08, 2024 by Dow JonesKamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance, from 7:00AM ET on Wednesday May 08, 2024 by Dow Jones
7:00AM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kamada Ltd | 302.9M | 20.6x | -22.48% |
Sutro Biopharma Inc | 345.6M | -2.2x | --- |
Agenus Inc | 329.5M | -1.2x | --- |
Karyopharm Therapeutics Inc | 114.1M | -0.8x | --- |
FibroGen Inc | 119.4M | -0.5x | --- |
Anika Therapeutics Inc | 380.3M | -4.9x | --- |
Company Information
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Contact Information
- Headquarters
- 2 Holtzman St., Science ParkREHOVOT, Israel 7670402
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Lilach Asher Topilsky
- Chief Executive Officer
- Amir London
- Deputy Chairman of the Board
- David Tsur
- Chief Financial Officer
- Chaime Orlev
- Senior Vice President - Scientific Affairs
- Ruth Wolfson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $302.9M |
|---|---|
Revenue (TTM) | $149.5M |
Shares Outstanding | 57.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $0.26 |
Book Value | $4.25 |
P/E Ratio | 20.6x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | 12.0x |
Operating Margin | 9.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
